CoChat

Novel drug targets for idiopathic pulmonary fibrosis

Open access
Sgalla, Giacomo, Cocconcelli, Elisabetta, Tonelli, Roberto, Richeldi, Luca · 2016 · Expert Review of Respiratory Medicine
Cited by 42

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disorder of unknown cause with a highly variable and unpredictable clinical course. The advances made in deciphering IPF pathobiology over the last decades have led to the approval of two anti-fibrotic molecules, pirfenidone and nintedanib, that showed to be effective in significantly reducing the rate of progression of the disease. Such pharmacological breakthroughs represent a dramatic change in the management of these patients and are reflected in updated international guidelines. However, the need to find a cure for this devastating disease remains unmet and the development of novel therapeutic agents remains hurdled by several factors. Here, we review the latest insights into therapeutic approaches for IPF and the available evidence for the most promising novel compounds currently under development, and discuss the challenges and evolution of IPF clinical research over the next few years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/17476348.2016.1152186

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 42

Metadata

Authors
Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L.
Venue
Expert Review of Respiratory Medicine
Published
2016-02-26
Volume
10
Issue
4
Pages
393-405
ISSN
  • 1747-6348 (ISSN-L)
  • 1747-6356
OpenAlex
W2265234633
Cited by
42
References
23
FWCI
2.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel drug targets for idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1586/17476348.2016.1152186
The paper
Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L. (2016). Novel drug targets for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine. https://doi.org/10.1586/17476348.2016.1152186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.